WallStSmart

GE HealthCare Technologies Inc. (GEHC)vsMaxCyte Inc (MXCT)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

GE HealthCare Technologies Inc. generates 63423% more annual revenue ($20.98B vs $33.03M). GEHC leads profitability with a 9.1% profit margin vs -135.1%. GEHC earns a higher WallStSmart Score of 57/100 (C).

GEHC

Buy

57

out of 100

Grade: C

Growth: 4.0Profit: 6.5Value: 7.3Quality: 4.3
Piotroski: 2/9Altman Z: 1.34

MXCT

Avoid

30

out of 100

Grade: F

Growth: 2.7Profit: 2.0Value: 6.7Quality: 8.0
Piotroski: 2/9Altman Z: 2.78
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

GEHCUndervalued (+43.4%)

Margin of Safety

+43.4%

Fair Value

$139.80

Current Price

$63.47

$76.33 discount

UndervaluedFair: $139.80Overvalued
MXCTUndervalued (+44.7%)

Margin of Safety

+44.7%

Fair Value

$1.32

Current Price

$0.84

$0.48 discount

UndervaluedFair: $1.32Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

GEHC2 strengths · Avg: 8.0/10
P/E RatioValuation
14.7x8/10

Attractively priced relative to earnings

Price/BookValuation
2.8x8/10

Reasonable price relative to book value

MXCT2 strengths · Avg: 9.5/10
Price/BookValuation
0.5x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.109/10

Conservative balance sheet, low leverage

Areas to Watch

GEHC4 concerns · Avg: 2.8/10
PEG RatioValuation
1.724/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

EPS GrowthGrowth
-30.9%2/10

Earnings declined 30.9%

Altman Z-ScoreHealth
1.342/10

Distress zone — elevated risk

MXCT4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$90.34M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Return on EquityProfitability
-23.6%2/10

ROE of -23.6% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : GEHC

The strongest argument for GEHC centers on P/E Ratio, Price/Book.

Bull Case : MXCT

The strongest argument for MXCT centers on Price/Book, Debt/Equity.

Bear Case : GEHC

The primary concerns for GEHC are PEG Ratio, Piotroski F-Score, EPS Growth.

Bear Case : MXCT

The primary concerns for MXCT are EPS Growth, Market Cap, Piotroski F-Score.

Key Dynamics to Monitor

GEHC profiles as a value stock while MXCT is a turnaround play — different risk/reward profiles.

MXCT carries more volatility with a beta of 1.57 — expect wider price swings.

GEHC is growing revenue faster at 7.4% — sustainability is the question.

GEHC generates stronger free cash flow (112M), providing more financial flexibility.

Bottom Line

GEHC scores higher overall (57/100 vs 30/100). MXCT offers better value entry with a 44.7% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

GE HealthCare Technologies Inc.

HEALTHCARE · MEDICAL DEVICES · USA

GE HealthCare Technologies Inc. provides medical technology, pharmaceutical diagnostics, and digital solutions in the United States. The company is headquartered in Chicago, Illinois.

MaxCyte Inc

HEALTHCARE · MEDICAL DEVICES · USA

MaxCyte Inc. (MXCT) is a pioneering company in the field of cell-engineering, distinguished by its innovative Flow Electroporation® technology, which facilitates the efficient and scalable introduction of nucleic acids and proteins into various cell types. Serving a diverse clientele that includes leading biopharmaceutical companies and prominent research institutions, MaxCyte is strategically positioned in the burgeoning cell and gene therapy market. The company's cutting-edge platforms are integral to the development of novel cell-based therapies and vaccines, allowing it to seize substantial growth opportunities within the healthcare landscape. Committed to advancing transformative medical solutions, MaxCyte is set to meet the increasing global demand for innovative therapeutic approaches.

Visit Website →

Want to dig deeper into these stocks?